Astex Pharmaceuticals and Newcastle University formed a strategic alliance with Hoffmann-La Roche to license breast cancer compounds.
2 reports, 2 independent
Updated Jul 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Astex Pharmaceuticals and Newcastle University formed a strategic alliance with Hoffmann-La Roche to license breast cancer compounds.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.Also in this story
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- Adagene Inc. presented data regarding its ADG126 therapy at a CSCO meeting, with mentions of locations including Jinan and Suzhou.
- Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.
The entities involved
-
Astex Pharmaceuticals
pharmaceutical company
Nothing else this week.
-
Hoffmann-La Roche
Swiss healthcare company